ORBITAL: Open-Label Primary Care Study: Rosuvastatin Based Compliance Initiatives Linked To Achievement Of LDL Goals

This study has been withdrawn prior to enrollment.

( study cancelled prior to FSI )

Study NCT00396240 Information provided by AstraZeneca

First Received: November 3, 2006 Last Updated: March 25, 2009 History of Changes

No Study Results Posted on ClinicalTrials.gov for this Study

Study was withdrawn before participants were enrolled.

Study Status:	This study has been withdrawn prior to enrollment.
Estimated Study Completion Date:	No date given
Estimated Primary Completion Date:	No date given